Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions
Blanch-Rubió et al.,
Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory..,
Aging, doi:10.18632/aging.104117
Retrospective 2,102 rheumatology patients in Spain showing no significant difference in cases with vitamin D supplementation. Details of vitamin D supplementation are not providied - other patients may have also independently taken vitamin D.
risk of case, 8.0% lower, RR 0.92, p = 0.68, treatment 62 of 1,303 (4.8%), control 47 of 799 (5.9%), adjusted per study.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Blanch-Rubió et al., 20 Oct 2020, retrospective, Spain, peer-reviewed, mean age 66.4, 10 authors, dosage not specified.
Abstract: www.aging-us.com
AGING 2020, Vol. 12, No. 20
Research Paper
Influence of anti-osteoporosis treatments on the incidence of COVID19 in patients with non-inflammatory rheumatic conditions
Josep Blanch-Rubió1,2,*, Natalia Soldevila-Domenech3,7,*, Laura Tío2, Jone Llorente-Onaindia2,
Manuel Ciria-Recasens1,2, Luciano Polino2, Alba Gurt5, Rafael de la Torre3,6,7, Rafael
Maldonado2,4,§, Jordi Monfort1,2,§, and the Covidmar Study Group#
1
Rheumatology Service, Hospital del Mar, Passeig Marítim, Barcelona 08003, Spain
IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain
3
Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIMInstitut Hospital del Mar d’Investigacions Mèdiques, PRBB, Barcelona 08003, Spain
4
Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra,
PRBB, Barcelona 08003, Spain
5
CAP Vila Olímpica, Parc Sanitari Pere Virgili, Barcelona 08003, Spain
6
Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERObn), Instituto de Salud
Carlos III (ISCIII), Madrid 28029, Spain
7
Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, Barcelona 08003, Spain
*Equal contribution
§
Equally supervised this work
#
A list of authors and their affiliations appears in Acknowledgments
2
Correspondence to: Rafael Maldonado; email: rafael.maldonado@upf.edu
Keywords: denosumab, zoledronate, calcium, vitamin D, anti-resorptive drugs, COVID-19
Received: July 21, 2020
Accepted: September 9, 2020
Published: October 20, 2020
Copyright: © 2020 Blanch-Rubió et al. This is an open access article distributed under the terms of the Creative Commons
Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
ABSTRACT
Coronavirus disease 19 (COVID-19) is currently a global pandemic that affects patients with other pathologies.
Here, we investigated the influence of treatments for osteoporosis and other non-inflammatory rheumatic
conditions, such as osteoarthritis and fibromyalgia, on COVID-19 incidence. To this end, we conducted a crosssectional study of 2,102 patients being treated at the Rheumatology Service of Hospital del Mar (Barcelona,
Spain). In our cohort, COVID-19 cumulative incidence from March 1 to May 3, 2020 was compared to population
estimates for the same city. We used Poisson regression models to determine the adjusted relative risk ratios for
COVID-19 associated with different treatments and comorbidities. Denosumab, zoledronate and calcium were
negatively associated with COVID-19 incidence. Some analgesics, particularly pregabalin and most of the studied
antidepressants, were positively associated with COVID-19 incidence, whereas duloxetine presented a negative
association. Oral bisphosphonates, vitamin D, thiazide diuretics, anti-hypertensive drugs and chronic nonsteroidal anti-inflammatory drugs had no effect on COVID-19 incidence in the studied population. Our results
provide novel evidence to support the maintenance of the main anti-osteoporosis treatments in COVID-19
patients, which may be of particular relevance to elderly patients affected by the SARS-CoV-2 pandemic.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit